Artemisinin induces omeprazole metabolism in human beings

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 2, 1998, Pages 160-167

  Svensson, Ulrika S H ^a   Ashton, Michael ^b   Hai, Trinh Ngoc ^b   Bertilsson, Leif ^b   Huong, Dinh Xuan ^b   Van Huong, Nguyen ^b   Niêu, Nguyen Thi ^b   Sy, Nguyen Duy ^b   Lykkesfeldt, Jens ^b   Công, Le Dinh ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; OMEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; DOSE TIME EFFECT RELATION; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALARIA; MALE; METABOLIC ACTIVATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; REFERENCE VALUES; SESQUITERPENES; TIME FACTORS;

EID: 13144307057     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90149-7     Document Type: Article

References (18)

1. China Cooperative Research Group on Qinghaosu and its Derivatives as Antimalarials. Metabolism and pharmacokinetics of qinghaosu and its derivatives. J Tradit Chin Med 1982;2:25-30.
2. Zhu DY, Huang BS, Chen ZL, Yin ML, Yang YM, Dai ML, et al. Isolation and identification of the metabolite of artemisinine in humans. Chung Kuo Yao Li Hsueh Pao 1983;4:194-7.
3. Lee IK, Hufford CD. Metabolism of antimalarial sesquiterpene lactones. Pharmacol Ther 1990;48:345-55.
4. Leskovac V, Theoharides AD. Hepatic metabolism of artemisinin drugs. I: Drug metabolism in rat liver microsomes. Comp Biochem Physiol 1991;99C:383-90.
5. Ashton M, Sy ND, Gordi T, Hai TN, Thach DC, Huong NV, et al. Evidence for time-dependent artemisinin kinetics in adults with uncomplicated malaria. Pharm Pharmacol Lett 1996;6:127-30.
6. Hassan Alin M, Ashton M, Kihamia C, Mtey G, Björkman A. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falcipurum malaria patients. Trans R Soc Trop Med Hyg 1996;90:61-5.
7. Chang M, Dahl ML, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-63.
8. Ged CRJ, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, et al. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28:373-87.
9. Bienvenu T, Rey E, Pons G, d'Athis P, Olive G. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. Int J Clin Pharmacol Ther Toxicol 1991;29:441-5.
10. Bertilsson L, Tybring G, Widén J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol 1997;44:186-9.
11. Andersson TMJ, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994;37:597-604.
12. Edlund PO, Westerlund D, Carlqvist J, Bo-Liang W, Yunhua J. Determination of artesunate and dihydroartemisinine in plasma by liquid chromatography with post-column derivatization and UV-detection. Acta Pharm Suec 1984;21:223-34.
13. Lagerstrom PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984;309:347-56.
14. Lykkesfeldt J, Loft S, Poulsen HE. Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by high-performance liquid chromatography to measure human CYP 3A activity. J Chromatogr B Biomed Sci Appl 1994;660:23-9.
15. Houston JB. Drug metabolite kinetics. Pharmacol Ther 1982;15:521-52.
16. Roh H, Tybring G, Yamada H, Cha Y, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6:547-51.
17. Regårdh C, Andersson T, Lagerström P, Lundborg P, Skånberg I. The pharmacokinetics of omeprazole in humans: a study of single intravenous and oral doses. Ther Drug Monit 1990;12:163-72.
18. Böttiger Y, Tybring G, Götharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997;62:384-91.